What happens to your weight when you stop taking Wegovy

What the trial data actually shows about stopping

The clearest picture comes from the STEP 1 withdrawal extension, which followed participants for a further year after they stopped semaglutide 2.4mg. On average, people regained around 6.9 percentage points of body weight within 12 months, roughly two-thirds of what they had lost during the active treatment period. Cardiometabolic improvements followed a similar pattern: waist circumference, blood pressure, and blood glucose measures all moved back toward baseline values.

That is not a reason to panic if you need to stop, but it is worth understanding before you make the decision. Wegovy does not permanently alter how your body regulates weight; it manages the biological environment while you take it. The speed at which Wegovy works gives some clue to what happens in reverse, it took weeks for appetite suppression to build, and it takes weeks to unwind.

The STEP 1 trial, published in the New England Journal of Medicine, remains the most cited evidence base for semaglutide 2.4mg outcomes, including the withdrawal phase. Cite it to yourself when weighing up what stopping means in practice.

Why the body responds this way, and why it is not a willpower issue

Semaglutide works on GLP-1 receptors involved in hunger signalling and gastric emptying. While you are taking it, appetite is consistently lower and the feeling of fullness arrives sooner. Stop the injections, and those receptor effects fade as the medicine clears, a process that takes several weeks given semaglutide's long half-life.

Obesity is a condition shaped by biology, not character. The regain that follows stopping reflects the underlying physiology reasserting itself, not a lack of resolve. Understanding this matters because some people stop treatment assuming the habits they have built will hold everything in place. They can help (lifestyle changes made during treatment have real value) but they are unlikely to fully offset the return of a stronger appetite on their own.

If you are weighing this up and wondering whether stopping semaglutide is safe, the short answer is that it is medically safe for most people; the main concern is weight and the conditions it affects, not an acute risk from discontinuation itself.

Reasons people stop, and what each one changes about the calculation

People stop Wegovy for different reasons, and the right approach varies with each one. Cost is one of the most common: treatment involves ongoing prescription costs, and a month that stretches the budget (say, an unexpected bill landing the same week as a renewal) can tip the balance. If cost is the driver, it is worth knowing that a pause is not necessarily permanent, and a prescriber can discuss whether a lower maintenance dose might be tolerable and more affordable than stopping entirely.

Side effects are another reason. GI symptoms (nausea, loose stools, reflux) are most pronounced during dose increases and often settle. If they have not settled, that conversation belongs with your prescriber before you stop, because adjusting the dose schedule is sometimes enough. You can read more about how to stop taking Wegovy safely if the decision is already made.

Some people reach a point where they feel they have achieved enough and want to test life without it. That is a legitimate choice. The evidence suggests having a clear plan for maintaining the lifestyle changes made during treatment (regular activity, protein-forward eating, monitoring weight) improves outcomes after stopping, though it does not eliminate regain for most people.

NICE's guidance on semaglutide for weight management, available in NICE technology appraisal TA875, notes that treatment should be reviewed if less than five percent of weight has been lost after six months on the maintenance dose. That review is a two-way conversation, it might result in stopping, or in reassessing the overall plan.

Planning what comes next

The most useful thing you can do before stopping is to have a structured conversation with your prescriber. That means discussing what you are hoping to maintain, what lifestyle anchors are already in place, and whether a planned taper (rather than an abrupt stop) is appropriate for your situation. There is no universal taper protocol, the timing of when to stop Wegovy depends on individual clinical history.

Monitoring weight monthly after stopping gives you an early signal if regain is accelerating. A small, steady increase in the months after stopping is common; a rapid return toward starting weight within three or four months may indicate that ongoing medical support would be beneficial. The clinical criteria around when stopping is appropriate are worth understanding before the decision is finalised.

One practical detail worth noting: if your renewal is due around a bank holiday or a period you know will be disrupted, it is easier to plan a deliberate pause than to let a logistical gap become an accidental stop. Continuity matters for clinical stability. If you are thinking about your options more broadly, our treatment overview explains what weight management looks like across different starting points. If you have specific questions for a clinician, our clinical team is available, and you can check your eligibility if you are considering restarting or starting for the first time.